Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 10:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Corticosteroid Injection Clear all
Completed Phase 4 Interventional

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

NCT05626478
View directory record Official record
Conditions
Corneal Edema, Corneal Defect, Anterior Chamber Inflammation, Ocular Pain, Corneal Staining, Visual Outcome, CME - Cystoid Macular Edema
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 12, 2026, 10:35 AM EDT
Completed No phase listed Observational

Outcome Following Hylan F- 20 (Synvisc) + Corticosteroid Injections for the Treatment of Osteoarthritis of the Knee

NCT00312533
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Hylan F- 20
Drug
Lead sponsor
Steadman Hawkins Research Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 24, 2008 · Synced Sep 12, 2026, 10:35 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

NCT05885555
View directory record Official record
Conditions
Primary Immune Thrombocytopenia (ITP)
Interventions
Ianalumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 4 Interventional Results available

Erector Spinae Plane Block Versus Conventional Analgesia in Complex Spine Surgery

NCT04156581
View directory record Official record
Conditions
Opioid Use, Pain, Postoperative
Interventions
Bupivacaine, Dexamethasone, Saline
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

Protein and Energy Metabolism in Pediatric Crohn's Disease

NCT00583232
View directory record Official record
Conditions
Crohn's Disease, Protein Metabolism, Energy Metabolism
Interventions
Stable isotope infusions
Drug
Lead sponsor
Indiana University
Other
Eligibility
6 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 12, 2026, 10:35 AM EDT
Active, not recruiting Not applicable Interventional

INJECTABLE COLD ENERGY THERAPY FOR THE MANAGEMENT OF CHRONIC PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE

NCT06700109
View directory record Official record
Conditions
Osteoarthritis (OA) of the Knee
Interventions
Neural Ice, Triamcinolone acetate
Device · Drug
Lead sponsor
Brixton Biosciences, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
15
States / cities
Larkspur, California • Washington D.C., District of Columbia • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 12, 2026, 10:35 AM EDT
Recruiting Phase 3 Interventional

Topical Cryotherapy and Keloid/Hypertrophic Scars

NCT07336368
View directory record Official record
Conditions
Keloid Scars, Hypertrophic Scars
Interventions
Cryotherapy with liquid nitrogen, Intralesional Triamcinolone 10 mg/ml
Device · Drug
Lead sponsor
Sonal Choudhary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer

NCT01378091
View directory record Official record
Conditions
Prostate Cancer
Interventions
Lenalidomide, Docetaxel, Prednisone
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2016 · Synced Sep 12, 2026, 10:35 AM EDT
Completed No phase listed Observational Results available

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS

NCT04138758
View directory record Official record
Conditions
COPD
Interventions
Tiotropium bromide + Olodaterol, LABA/ICS
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
42,953 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 4 Interventional Results available

Fall Epidemic Viral Pediatric Study

NCT01192178
View directory record Official record
Conditions
Asthma
Interventions
FLOVENT™ DISKUS™ 100 mcg BID, ADVAIR™ DISKUS™ 100/50 mcg BID
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 11 Years
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
38
States / cities
Tucson, Arizona • Bakersfield, California • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 12, 2026, 10:35 AM EDT
Terminated Phase 1 Interventional Results available

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

NCT04840615
View directory record Official record
Conditions
Mesothelioma
Interventions
LMB-100, ipilimumab, Diphenhydramine, Famotidine, Acetaminophen, Dexamethasone, Biopsy, FDG-PET, CT CAP, MRI, ECG, Echocardiogram
Biological · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 12, 2026, 10:35 AM EDT
Terminated Phase 4 Interventional Results available

A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal

NCT02317276
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Triamcinolone 0.1%
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Not applicable Interventional Results available

Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients

NCT04450108
View directory record Official record
Conditions
Asthma, Asthma in Children
Interventions
Vivatmo pro FeNO Test
Diagnostic Test
Lead sponsor
Bosch Healthcare Solutions GmbH
Industry
Eligibility
7 Years to 80 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Birmingham, Alabama • Bakersfield, California • White Marsh, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus

NCT00007358
View directory record Official record
Conditions
Congenital Heart Block, Neonatal Lupus, Atrioventricular Nodal Dysfunction, Myocardial Injury
Interventions
Dexamethasone or other corticosteroid
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2008
U.S. locations
4
States / cities
New Haven, Connecticut • Livingston, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)

NCT00562497
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Prochymal®, Placebo, Corticosteroid
Drug · Other
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
45
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 2 Interventional Results available

Randomized Trial for Mixed Acute Rejection

NCT00771875
View directory record Official record
Conditions
Graft Rejection
Interventions
Rabbit Antithymocyte Globulin (RATG), Rituximab, Bortezomib, Acetaminophen, Antihistamine, Methylprednisolone
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Not applicable Interventional Results available

Do Corticosteroid Injections During Total Knee Replacement Improve Early Clinical Results?

NCT00492973
View directory record Official record
Conditions
Osteoarthritis, Post-traumatic; Arthrosis
Interventions
methylprednisolone acetate, active comparator
Drug
Lead sponsor
New Lexington Clinic
Other
Eligibility
18 Years to 95 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 12, 2026, 10:35 AM EDT
Recruiting No phase listed Observational

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

NCT06627335
View directory record Official record
Conditions
Pregnancy Related, Atopic Dermatitis
Interventions
Ruxolitinib Cream, TCS
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
14 Years and older · Female only
Enrollment
5,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01009463
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
94
States / cities
Birmingham, Alabama • Jasper, Alabama • Peoria, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Sep 12, 2026, 10:35 AM EDT
Enrolling by invitation Not applicable Interventional

A Longitudinal, Multi-Center Safety Study of Autologous Adult Adipose-Derived Regenerative Cell Injection Into Chronic Partial-Thickness Rotator Cuff Tears

NCT05400798
View directory record Official record
Conditions
Partial Thickness Rotator Cuff Tear
Interventions
Adipose Derived Regenerative Cells, Corticosteroid
Device
Lead sponsor
InGeneron, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • La Mesa, California • Pasadena, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 12, 2026, 10:35 AM EDT
Terminated Phase 4 Interventional Results available

Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients

NCT00522548
View directory record Official record
Conditions
Transplants and Implants
Interventions
Enteric coated mycophenolate sodium, Mycophenolate mofetil
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 12, 2026, 10:35 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

BREATHE: An Efficacy-implementation Trial Among Black Adults With Uncontrolled Asthma

NCT05341726
View directory record Official record
Conditions
Asthma
Interventions
BREATHE Intervention, Control Intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Beacon, New York • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 12, 2026, 10:35 AM EDT
Withdrawn Phase 2 Interventional

Corticosteroids in Community Acquired Pneumonia

NCT04652414
View directory record Official record
Conditions
Community-acquired Pneumonia, Cognition Disorder
Interventions
Prednisone, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 12, 2026, 10:35 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma

NCT05935332
View directory record Official record
Conditions
Asthma
Interventions
RPT193, Placebo
Drug · Other
Lead sponsor
RAPT Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
San Jose, California • Stockton, California • Westminster, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 12, 2026, 10:35 AM EDT